CTAC Annual Report 2015-2016 by CTAC

ANNUAL annual REPORT report –2016 2015 2014–2015

learn. Pronunciation: /ləːn

VERB (past and past participle learned /ləːnt, ləːnd/) Gain or acquire knowledge of or skill in (something) by study, experience, or being taught

grow. Pronunciation: /ɡrəʊ /

VERB (past grew /ɡruː/; past participle grown /ɡrəʊn/) To become better or improved in some way : To become more developed, mature, etc.

share. Pronunciation: /ʃɛː /

VERB To tell (as thoughts, feelings, or experiences) to others

lead. Pronunciation: /liːd /

VERB (past and past participle led /lεd/) To guide someone or something along a way

Table of Contents Joint Letter from the Chair and the Interim ED

Who We Are 3 Our Projects and Programs 4 2016-2019 Strategic Plan 9 Events and Activities 10 2015-2016 by the Numbers 12 Financial Statements 13 2015-2016 Funders and Partners 14

Joint Letter from the Chair & the Interim ED

Dear friends, Fiscal year 2015-2016 at CTAC was chock full of febrility. The last two years’ themes of learning, growing, sharing and leading continued to animate our work and reflect the passion that motivates us. We continued to grow steadily and make a positive difference under sometimes turbulent conditions that resulted from unexpected organizational changes. This report highlights some of our achievements throughout the year, as well as what you can expect in the year to come. The core of our project activities in 2015-2016 focused on ensuring treatment access and equity through our participation with patient groups and policymakers. CTAC is committed to increasing the capacity of people in Canada living with HIV and with HIV/hepatitis C virus (HCV) coinfection and those at risk and community-based and health service providers, to identify and overcome barriers across the HIV and HCV continuum of care. Throughout the year, CTAC undertook the gargantuan task of developing and refining the Treatment Map [TxMAP]. The TxMAP is an interactive tool and resource that enhances the ways people are able to access information on treatment availability nationwide; empowers and equips people to better navigate structural barriers and to act as agents of change; stimulates a national discussion on treatment access issues; strengthens avenues for access to treatment for people affected by HIV and HCV. The TxMAP helps community members and service providers learn the regulatory status, accessibility, and eligibility requirements for every HIV and hepatitis C treatment available in Canada. There is no other single-source repository of information of its kind in Canada. CTAC partnered with CATIE and PositiveLite.com to lead the development of a Canadian Consensus Statement on the health and prevention benefits of HIV antiretroviral medications and HIV testing. We hope the Consensus Statement will be endorsed broadly by healthcare workers, communitybased organizations and policymakers serving the HIV community to help guide individuals and organizations in building a comprehensive response to the HIV epidemic. On September 25th and 26th, 2015, CTAC hosted the Treatment Development and Market Access (TDMA) Conference at the Courtyard Marriott in Toronto. Welcoming over 45 attendees, this was CTAC’s first such conference to bring together patient groups to discuss treatment access, pricing, and regulatory systems in Canada. Every region in Canada was represented and all attendees were able to engage with speakers, one another, and CTAC staff in discussions around contemporary issues surrounding HIV and hepatitis C (HCV) treatment access. TDMA participants included front-line service providers, physicians, researchers, pharmacists, patient groups, board members, executive directors, and other patient advocates. 74% of all participants were people with lived experience of HIV/AIDS and/or HCV. As part of CTAC’s evaluation process, participants were encouraged to share what they

hoped to learn about, what issues they wanted to discuss, and what issue areas were most important to them. Ultimately, there was great consensus on the wants and needs of participants and the most popular among them were a discussion on a panCanadian prescription drug program; an opportunity to learn more about the treatment pipelines in HIV and HCV medicines; a greater understanding of CTAC perspectives and activities relating to treatment access; and a chance to hear from other patient groups across the country. Access to treatment is critical for the best possible health outcomes for people living in Canada, and CTAC is well positioned as a leader to ensure that barriers faced by people living with HIV and with HIV/HCV co-infection are addressed. CTAC participates in the Common Drug Review process by adding patient voices to influence timely listing recommendations to participating provincial, territorial and federal drug plans. In fact, our contributions have been recognized by CADTH on their website as one of the 17 patient groups who have contributed five or more input submissions in the first five years of patient engagement. When preparing a patient input submission at CTAC, we hold a national consultation webinar to present clinical trial data on the new medication under consideration and provide a webbased, anonymous feedback form so that as many patients as possible can be represented in CTAC’s submission. CTAC was founded in 1996 as a national body representing people living with HIV/AIDS across Canada—a body that would inform public policy in response to the complex issues arising from the then new combination antiretroviral therapies used to treat HIV infection. In this, our 20th year of existence, we launched an exciting three-year Strategic Plan to reinvigorate our work. With this plan, we are boldly re-establishing ourselves as national and regional advocates, key opinion leaders, and partners in the policy space that is our mandate: treatment, care and support for our communities of people living with HIV/ AIDS and HIV/HCV co-infection. The CTAC Board and staff are looking forward to the year ahead and beyond, as we make major progress in breaking down the barriers to HIV and HCV treatment and diagnostics. We will continue to increase health promotion awareness and interventions, as well as increase and strengthen collaboration among various stakeholders. We will continue to present at workshops and meetings, and increasingly use multimedia platforms (i.e., webinars, videos and other social media platforms) to plan and deliver programs and services to address HIV and HCV, to promote information/knowledge transfer and dissemination, as well as identify potential policy and program interventions to redress barriers to treatment access across the country. We will also actively build our partnerships with regulated health professionals and organizations across regions, and enhance the capacity of front-line health, social service and community-based HIV, HCV, and sexual health organizations.

CTAC ANNUAL REPORT 2015-- 2016

In closing, we would like to thank all of the staff and Board members for their contributions to CTAC’s positive growth; our members for providing patient input and participating in the governance of our organization; our national partners and other key stakeholders for continued support; and, last but not least, all of our dedicated working group and steering committee members who have volunteered countless hours to ensure that our work reflects a community-driven response.

Terry Pigeon

Chair, Board of Directors

Barbara Santosuosso Interim Executive Director

The Board of Directors Arthur ‘Dave’ Miller

Lynn Thompson

Treasurer and Atlantic Region Director

At Large Director

Christian Hui

Maggie McGinn

Ontario Region Director

Western Region Director

Enrico Mandarino

Mikiki

At Large Director

Vice-Chair and At Large Director

Harlon Davey

Shannon Kelley

Ontario Region Director

At Large Director

Jonathan Postnikoff

Terry Pigeon

Secretary and Pacific Region Director

Chair and Québec Region Director

Who We Are

The Team Adam Cook

Melissa Potvin

Policy Researcher

Communications Coordinator

Anna Li

Rounak Faizi Khan

Research Assistant

Stakeholder Engagement & Special Projects

Barbara Santosuosso

Shane Patey

Program Manager

Executive Director

Eliza Lozada

Shraddha Shah

Bookkeeper

Finance and Administration Manager

Glenn Betteridge

Terry Santoni

Policy Researcher

Research and Program Support

CTAC ANNUAL REPORT 2015-- 2016

Our Projects & Programs

Treatment Map — Changing the landscape of HIV and hepatitis C treatment access in Canada CTAC revealed the first beta version of the Treatment Map (TxMAP) – formerly known as the Treatment Access Map – at national partner CATIE’s bilingual forum in October 2015. The Treatment Map is a comprehensive, indispensable and one-of-a-kind online tool that allows community members, service providers, and policy researchers to access information about HIV and hepatitis C treatments available through provincial, territorial, and federal public drug plans in Canada. Post-CATIE Forum, the Treatment Map went into its user-testing phase. Fifteen stakeholders, including community members and service providers, participated in this process. Feedback was enthusiastic and positive, and most of the suggestions made involved making minor changes to the graphical user interface. CTAC staff completed these changes before the end of the fiscal year. Data service provider, IMS Brogan, supplies CTAC with much of the information that was included in the beta version of the Treatment Map. To supplement the data provided by IMS Brogran, CTAC reached out to public drug plan managers and contacts from the pharmaceutical industry to review the data, and to ensure its integrity is maintained. The TxMap was updated to reflect any inconsistencies. The full launch of the Treatment Map occurred in March 2016, with broad dissemination pending.

CTAC ANNUAL REPORT 2015-- 2016

Consensus Statement — A holistic community response that combines HIV treatment and prevention, health and human rights CTAC, in partnership with CATIE and PositiveLite.com (the “working group,” collectively), continued to develop a community-driven, holistic response that would combine HIV treatment and prevention for a Canadian consensus statement through rigorous research, consultation and discussion informed by PHAs and affected communities. At the national CAHR Conference in April 2015, the working group held a national consultation attended by community members, staff of frontline service organizations, health care professionals and other interested people. Participants identified key issues related to policy and regulation, health systems, and frontline programming. Participants also brought forth the lived experiences of people living with HIV, HIVnegative people, and people who didn’t know their HIV status. Participants suggested that community members needed a draft statement to reflect upon and respond to. From May to October 2015, the working group drafted the Consensus Statement based on notes from the consultation, statements and guidelines prepared by organizations in Canada and internationally, and additional research into the key issues. At a CATIE Forum workshop attended by 25 community members, the working group presented a draft Consensus Statement for feedback. A professional slide-show presentation and questionnaire were used to facilitate discussion and to collect feedback. The working group sent the draft Consensus Statement to more than 40 key opinion leaders in the community-based HIV sector in Canada for their feedback between December 2015 and March 2016. They subsequently met to consider and incorporate that feedback into a revision of the Consensus Statement before proceeding with a broad online consultation open to all. At that time, the working group developed an online survey in French and English to solicit community input on the key principles underlying the Consensus Statement, and on the statements to guide the Canadian community-based response in relation to the use of antiretrovirals as treatment and as prevention, and the role of HIV testing in efforts to curb the HIV epidemic in Canada.

Treatment Development and Market Access Conference 2015 On September 25-26th, 2015, CTAC hosted the TDMA 2015 Conference. There were more than 40 participants, with more than half of them attending on scholarship from outside the Greater Toronto Area. 74% of attendees identified as living with HIV/AIDS and/or hepatitis C. CTAC received evaluations from the TDMA Conference, and participants positively rated the conference (the majority of weighted responses were 4 or 5 on a 5-point scale) for its presentations, networking opportunities, and speakers’ panel. Participants were extremely excited about CTAC’s Treatment Map as well as CTAC’s “Introduction to the Common Drug Review” informational video. Most participants reported they intended to use these tools at their home organizations. The highest rated portions of the two-day conference were the Treatment Map presentation and the Day 2 panel discussion. The Day 2 panel discussion (“Treatment Development and Real-World Evidence”) was rated with more 5/5 evaluations than any other presentation, and was called by one attendee “literally the best panel I’ve sat through.” Five of the speakers were interviewed on camera, discussing their work on treatment access issues in Canada. These short videos will be used to complement the final report. As part of our Treatment Development and Market Access activities, CTAC maintains membership in Action Hepatitis Canada (AHC)—a national coalition whose work engages government, policy makers, and civil society across Canada to promote hepatitis B and C prevention, improve access to care and treatment, increase knowledge and innovation, create public health awareness, build health-professional capacity, and support community-based groups and initiatives. In February 2016, CTAC policy researcher Adam Cook was unanimously elected to the Executive Committee of AHC (having previously sat on the Steering Committee since March 2014). On November 26th, 2015, AHC hosted a breakfast meeting at Queen’s Park (i.e., the Legislative Assembly of Ontario). CTAC, along with a patient with lived experience of hepatitis, both spoke and delivered presentations. The meeting was tremendously well-received. As a result of the meeting, CTAC was able to secure meetings with Ontario Members of Provincial Parliament, the Ontario Minister of Health and Long-Term Care, and two separate meetings with the Director of Ontario’s Exceptional Access Program (EAP), which is the regulatory body that controls access to HCV medications in Ontario. At these meetings, CTAC continuously advocated for an improved Common Drug Review process; evidence-based recommendations for eligibility requirements, and suggested an improved provincial response based on Quebec’s INESSS model, which scales back eligibility requirements for HCV treatments over a span of 6 years.

CTAC ANNUAL REPORT 2015-- 2016

Newcomers & Treatment Access — Developing tools to reduce barriers to treatment access for Ethiopian newcomers living with HIV and Pakistani newcomers living with hepatitis C Ethiopian Newcomers Living with HIV: A large amount of qualitative data has been collected through focus groups, needs assessment questionnaires with service providers, and in-depth interviews with community leaders. Participants in this project have indicated that the creation of a video outlining ways to reduce barriers in accessing HIV treatment would be the best possible way of engaging Ethiopian newcomers living with HIV, as it protects both their privacy and confidentiality. The content of this tool is following the principle of GIPA/MEPA, thus, culturally appropriate, sex-positive, non-stigmatizing, and based on evidence and experience in Amharic language. This tool will identify and describe barriers and challenges faced by Ethiopian newcomers living with HIV associated with immigration, and treatment access based on real case stories. It will be an invaluable support tool that addresses some of the barriers/issues that Ethiopian newcomers face in accessing HIV treatment and care in Canada. Pakistani Newcomers Living with HCV: Connecting with the Pakistani community around HCV has been very challenging. Needs assessment questionnaires as well as in-depth interviews were conducted with both service providers and the community. Working with the community has allowed for invaluable information to be collected, including increased understanding of modes of transmission in Pakistan. Barriers for treatment access were identified from the needs assessment data which included lack of knowledge of hepatitis C, insufficient support and information given from the primary caregiver to the patient about HCV treatment and eligibility criteria, wait time for seeing a specialist, treatment options available in Canada, etc. CTAC is now in the process of developing the resource tool with community involvement based on the feedback. In addition, CTAC participated in ICAD’s National Stakeholder Meeting – a one-day workshop on the Newcomer, Migrant and Refugee Health Project, held in Montreal on November 4, 2015. The purpose of the workshop was to identify strengths and gaps in services currently available to address HIV among newcomers and refugees across the continuum of care (prevention, testing, treatment, care and support) and to identify research gaps and priorities related to HIV and newcomer and refugee health. CTAC continues to be highly engaged with stakeholders on work related to addressing barriers facing newcomers living with HIV and/or HCV.

Advocacy to Expand Access to HCV Meds — A call to remove restrictions and improve consistency across Canada’s public drug plans CTAC staff worked with freelance health journalists on two HCV treatment and prison articles published in the news section of the Canadian Medical Association Journal. We provided background, referred journalist to health care providers, reviewed and analyzed CSC documents, met in-person and provided feedback over email, and shaped content and focus of articles. CTAC is a member of the Ontario HCV Provincial Teams Network. Representing over 17 clinics and community health care centres across Ontario, the Network has relied on CTAC for expert guidance and oversight into their advocacy activities. CTAC has provided three capacitybuilding webinars and workshops for the group and initiated an advocacy campaign that will see members engage their local members of parliament.

CTAC met with representatives of PHAC and the Federal Ministry of Health to discuss HCV treatment eligibility criteria and call for all jurisdictions in Canada to remove restrictive conditions keeping the cure out of reach of many Canadians. CTAC also met with provincial ministries of health and the Exceptional Access Program in Ontario to call for more open and consistent access to hepatitis C treatment in Canada. CTAC responded to calls for input and guidance from the Canadian Agency for Drugs and Technology in Health (CADTH), PHAC, Patented Medicines Pricing Review Board (PMPRB), and the pan-Canadian Pharmaceutical Alliance (pCPA). CTAC consulted with The Economist on a global scan of international hepatitis C plans, as experts on Canadian treatment access. CTAC was also interviewed or quoted in The Lancet, VICE, and CBC Radio. CTAC ANNUAL REPORT 2015-- 2016

HIV Pre-Exposure Prophylaxis (PrEP) — A risk-reduction strategy for HIV prevention PrEP has great potential to reduce HIV acquisition by people at heightened HIV risk. Yet, complex structural and institutional factors that trace the fault-line of health inequity in Canada may keep PrEP out of reach of marginalized people who could benefit most—including low income people, Aboriginal people, GBMSM, and sex workers. Based on published info sheets that policymakers and service providers can use in their work, CTAC led two national consultation webinars and participated in delivering focus group sessions with the purpose of building knowledge, awareness and capacity for community members to have their voices heard by the experts who will recommend whether Truvada for PrEP is a cost-effective way to reduce HIV transmission and should be listed on public drug programs. In fall of 2015, CTAC, along with convened PrEP advocates, met and formed CanPrEP—an alliance of community and community-minded people who have come together to increase access to and uptake of PrEP. The stated objectives of CanPrEP are to increase knowledge of regulatory processes Truvada as HIV PrEP must go through in order to get to those who need it most in Canada, and increase awareness of opportunities to address structural and institutional barriers to PrEP access in Canada. Based on feedback from the community, CTAC began its work on developing a set of info sheets that will address the following: 1.

Practical steps and considerations to access PrEP in Canada today

Approval and listing process that outlines access to PrEP in the future

Opportunities for intervention/action to promote timely and equitable access to PrEP

CTAC continues to correspond with industry, public payers and regulatory bodies to communicate community information needs and support capacity-building initiatives for health care, community, and service providers, as well as increase community mobilization efforts around opportunities for intervention and action to promote timely and equitable access to PrEP.

Pan-Canadian Pharmacare — Advocating for the same public drug coverage for all Canadians To CTAC, pan-Canadian pharmacare means that people, regardless of where they live in Canada or their socioeconomic status, can access the same high quality treatment options through one simplified mechanism. The term “pan-Canadian” recognizes that a universal national plan is needed, while taking account of the current reality of overlapping provincial, territorial and federal jurisdiction in relation to drug access, including reimbursement by public drug plans for costs incurred by individuals for medications or treatments. In the fall of 2015, CTAC and YouthCO created Pan-Canadian Pharmacare Pre-Election Campaign, a community toolkit for the HIV and hepatitis C communities to actively engage in the fall 2015 elections to advocate for pharmacare and make it an election issue. The toolkit provided several capacity-building tips and ways to get involved, including: •

actions individuals or communities could take before the Federal Election on October 19th, 2015

•

key messages that can be adapted by organizations

•

social media content ready to share via Facebook, Twitter, LinkedIn and more

•

campaign logo that can be uploaded onto websites and shared via social media

•

letters to the federal party leaders stating the urgent need for a pan-Canadian pharmacare strategy, and

•

a list of other organizations supporting pan-Canadian pharmacare and additional resource

CTAC ANNUAL REPORT 2015-- 2016

Sex, Me and HCV — Raising awareness and responding to hepatitis C virus transmission among gay, bi and other men who have sex with men CTAC worked with national and community-based HIV and gay men’s health organizations to respond to the emerging issue of increasing hepatitis C transmission among gay, bi and other men who have sex with men by developing video resources that are sex-positive, informed by evidence and experience, and that support harm reduction practices. These resources will engage GBMSM who want to know more about HCV and HIV/ HCV co-infection; understand ways to protect themselves and others; and follow avenues to improve their health. To assist health and psychosocial service providers in their work, CTAC also began to develop client-focused resources with background information and practical guidance. This project will aim to better inform service providers to work alongside GBMSM to protect and enhance these men’s sexual health and wellbeing.

CTAC TALKS! — Informing and educating through videos CTAC continues to produce informative videos—to educate, inform and motivate allies and stakeholders—around contemporary issues in HIV and HCV treatment access. This year, CTAC staff developed and produced five videos: Clinical Trials—current limitations and the need for greater representation; Drug Pricing in Canada — how much is too much?; Applying a public health approach to eradicate hepatitis; The need for access to PrEP & PrEP education; and Prisoner health: a promising model for hepatitis C testing and treatment. We continue to enjoy positive and enthusiastic responses from our viewers, and will continue to inform and engage using this medium.

CTAC ANNUAL REPORT 2015-- 2016

Strategic Plan In this, our 20th year of existence, we are pleased to launch an exciting three-year plan to reinvigorate our work. With this plan, we are boldly re-establishing ourselves as national and regional advocates, key opinion leaders, and partners in the policy space that is our mandate : treatment, care and support for our communities of people living with HIV and HIV/ hepatitis C co-infection.

2016 –2019 Strategic Plan

CTAC looks forward to an exciting and productive three years, by the end of which we will have made major progress in breaking down the barriers to treatment, care and support for people living with HIV/AIDS and HIV/ hepatitis C co-infection in Canada. 3 main goals:

By end of December 2019:

CTAC will ensure that advocacy, and policy engagement around treatment, care and support becomes central to its work;

2. CTAC will be widely recognized as Canada’s leading voice in access to HIV and HCV treatment, especially among our priority populations – and our stakeholders will be aware of all opportunities for engagement; and

CTAC will have developed our capacity to expand our reach, through partnerships and a diversified funding strategy.

Each of these goals and their respective objectives will inform our next three annual work plans. The strategic plan and its work plans will be tracked, monitored and evaluated by our Board of Directors, which will annually report on progress to our membership.

CTAC ANNUAL REPORT 2015-- 2016

Events and Activities CTAC board and staff are continuously engaging with our ever-expanding networks of service providers, and regional and national partners. We are regularly invited to local, regional and national events — workshops, research conferences, annual general

Presented Treatment Access Map (Poster presentation) • Canadian Association for HIV Research (CAHR) Conference, Toronto, ON: April 30 - May 3, 2015 • 10th International Conference on HIV Treatment and Prevention Adherence, Miami, FL: June 28-30, 2015

No More Silos Workshop • AIDS Coalition of Nova Scotia, Halifax, NS: April 21, 2015 • COCQ - SIDA, Montreal, QC: May 7, 2015

of developments in treatment

Access to Care, Treatment & Support for Improving Mental Health, presented at the Nova Scotia HIVSTBBI Knowledge Exchange and Health Promotion Forum

access and to identify innovative

Halifax, NS: June 19, 2015

meetings — to share information on HIV and HCV treatment and access issues. We keep abreast

HIV and HCV programs and services that promote access.

Treatment Access in Canada, presented at the Annual general meeting:

Treatment Access Map: Soft Launch, presented at the 2015 CATIE Forum: Making it Work from Planning to Practice Toronto, ON: October 15, 2015

From Research to Action: How to Translate Research into Policy Change, presented at the Canadian Symposium on HCV Montreal, QC: February 26, 2016

Treatment for Hepatitis C: Developments, Access and Advocacy, presented at the Alberta Council on HIV Conference Calgary, AB: March 8, 2016

AIDS Committee of Cambridge, Kitchener, Waterloo & Area, Kitchener, ON: June 17, 2015

No More Silos: HIV and Hepatitis C Funding and Service Integration, presented at the Alberta Council on HIV Conference

Hepatitis C: Treatment Developments, Access and Advocacy, presented at the Knowledge Exchange and Health Promotion Forum

CTAC Programmatic Update, presented at the Alberta Council on HIV Conference

Halifax, NS: June 19, 2015

Calgary, AB: March 8, 2016

Legacy piece, Positive Sex, the HIV Access to PrEP in Canada: Policy and Disclosure workshop, presented at Practice, presented at the Alberta the Annual meeting of Canadian Council on HIV Conference Aboriginal AIDS Network (CAAN) Calgary, AB: March 8, 2016 Vancouver, BC: July 15, 2015

Access to Care, Treatment & Support for Improving Mental Health, presented at the Pacific AIDS Network Fall Conference and AGM / Forum for Persons Living with HIV Vancouver, BC: September 22, 2015

CTAC ANNUAL REPORT 2015-- 2016

Attended 2015 CADTH Symposium Saskatoon, SK: April 12-14, 2015

8th IAS Conference on HIV Pathogenesis, Treatment & Prevention

24th Annual Canadian Conference on HIV/AIDS Research

Vancouver, BC: July 19-22, 2015

Toronto, ON: April 30-May 3, 2015

First Community Steering Committee Meeting: Stigma Index

11th Workshop on HIV/HCV Co-Infection

Toronto, ON: September 1, 2015

London, UK: June 11- 12, 2015

2015 Virology Education’s 11th International Workshop on HIV/HCV Co-Infection

CTAC’s Treatment Development and Market Access Conference Toronto, ON: September 25-26, 2015

London, UK: June 11-12, 2015

Nova Scotia HIV-STBBI Knowledge Exchange and Health Promotion Forum

2015 CATIE Forum: Making it Work from Planning to Practice Toronto, ON: October 15-16, 2015

Halifax, NS: June 17-19, 2015

International Meeting on Hepatitis Cure & Eradication 10th International Conference on HIV Treatment and Prevention Adherence

Vancouver, BC: November 11-12, 2015

Miami, FL: June 28-30, 2015

CWGHR Think Tank: Easing the Burden of Limited Financial Resources on People Aging with HIV: What can be done?

Annual meeting of Canadian Aboriginal AIDS Network (CAAN)

Toronto, ON: January 22, 2016

Vancouver, BC: July 15, 2015

Canadian Symposium on HCV Montreal, QC: February 26, 2016

2nd International HIV/Viral Hepatitis Co-infection Meeting

Alberta Council on HIV Conference

Vancouver, BC: July 17-18, 2015

Calgary, AB: March 8-9, 2016

Glenn Hillson Award

Advisory Board and Working Groups

On September 21, 2015, CTAC proudly honoured Louise Binder, co-founder of CTAC and long-time HIV advocate in Canada, with the 2015 Glen Hillson Award. Created in 2005 by CTAC to honour the memory of Glen Hillson, previous Vice Chair of CTAC and the Chair of British Columbia People with AIDS (BCPWA) Society, the Glen Hillson award recognizes HIV advocates who work tirelessly to support the HIV movement within Canada.

CTAC ANNUAL REPORT 2015-- 2016

•

AbbVie Community Advisory Board

•

Action Hepatitis Canada

•

Ethiopian Newcomers Living with HIV Working Group

•

Janssen Community Advisory Board

•

National Coordinating Committee on HIV and Aging

•

Ontario Working Group on Criminal Law and HIV Exposure

•

Pakistani Newcomers Living with HCV Working Group

•

Sex, Me & Hep C National Stakeholders Working Group

•

ViiV Community Advisory Board

2015 - 2016

by the numbers

Access to publicly funded medications in Canada overseen by 18 public drug plans. Navigating these plans can be challenging. CTAC advocates for affordable, equitable, and timely access to threatment throughout Canada for people living with HIV & HIV/hepatitis C co-infection.

8 997 39,595 4,440 985

average weekly impressions on our Facebook page unique page views on our website numbers of views on YouTube channel Twitter followers

2016 2015

2015 2014

Revenue

$707,161 $766,918

$725,261 $707,161

Expenses

$680,332 $735,239

$722,502 $680,332

Excess (deficiency) of revenue over expense

$26,829 $31,679

$2,759 $26,829

Fund balances beginning of year

$189,406 $203,069

$203,069 $200,310

Fund balances end of year

$221,085 $229,898

$189,406 $203,069

Financial Financial Statements Statements The following is a summary of The following is ainformation summary of selected financial selected financial from CTAC’s auditedinformation financial from CTAC’s audited financial statements for the year ending statements forFull thestatements year ending March 31, 2015. March 31, 2016. Full are available uponstatements request, are available through the upon CTACrequest, office. through the CTAC office.

Our auditors continue to give CTAC an unqualified, clean opinion

Revenue $766,918 $707,161

Public Health Agency of Canada

$603,855 (79%) $560,051 (79%)

Industry Funding

(16%) $112,800 (21%) $157,500

Program Sponsorship

(4%) $3,670 $30,000 (0.5%)

Other

$1,893 (1%) $4,310 (0.2%)

Expenses* HIV & HCV Programs

(86%) $629,387 $582,384 (86%)

Rent, telephone and utilities

$67,749 $62,690

(9%) (5%)

Administration and Other

$38,103 $35,258

(5%) (9%)

$735,239 $680,332

* Please note that some expenses have been reassigned between categories to more accurately reflect organizational spending.

-- 2016 CTAC CTACANNUAL ANNUAL REPORT REPORT 2015 2014–2015

1311

2015 –2016 Funders & Partners We would like to acknowledge the leadership, guidance and support provided by so many partners, community members, experts and other stakeholders whom we’ve had the pleasure to work with this past year. Your support allows us to continue to identify, develop and implement policy and program solutions promoting treatment access and the health and human rights of people living in Canada with HIV and HCV.

National Partners •

Canadian Aboriginal AIDS Network

•

Canadian Public Health Association

•

Canadian AIDS Society

•

Canadian Association for HIV Research

•

Canadian Working Group on HIV and Rehabilitation

•

Canadian HIV/AIDS Legal Network

•

CATIE

•

Canadian Institutes of Health Research

•

Interagency Coalition on AIDS and Development

Other Key Partners

•

Action Hepatitis Canada

•

Gay Men’s Sexual Health Alliance

•

AIDS Community Care Montreal

•

HIV Edmonton

•

Africans in Partnership Against AIDS

•

Alberta Community Council on HIV

Nova Scotia Advisory Commission on AIDS

•

AIDS Coalition of Nova Scotia

•

Ontario HIV Treatment Network

•

Best Medicines Coalition

•

Pacific AIDS Network

•

Canadian HIV/AIDS Black, African and Caribbean Network

•

Pakistani Newcomers Living with HCV Working Group

•

Canadian Positive People Network

•

People to People AID Organization

•

CanPrEP

•

PositiveLite.com

•

Ethiopian Association in the Greater Toronto Area

•

Positive Living BC

•

Ethiopian Newcomers Living with HIV Working Group

Sex, Me & Hep C National Stakeholders Working Group CTAC ANNUAL REPORT 2015-- 2016